Abstract
Many neurodegenerative diseases, referred to as misfolding diseases, are characterized by the formation and accumulation of pathological extracellular and intracellular misfolded aggregates. Ageing is considered the major risk factor for neurodegenerative disorders and, due to increase of mean lifespan, the clinical relevance is growing dramatically with a urgent need to find new effective therapeutic approaches. The intracellular antibody technology is a gene-based strategy which exploits the specificity of recombinant antibodies to neutralize or modify the function of intracellular and extracellular target antigens. Intrabodies can potentially recognize all the pathological conformers of a misfolding-prone protein, and therefore they are emerging as therapeutic agents for the treatment of misfolding diseases as well as molecular tools for the understanding of their pathogenesis.
Here we focus on the application of intrabodies against two major age-related neurodegenerative disorders, Alzheimer’s disease (AD) and Parkinson’s disease (PD) and the description of in vivo gene delivery systems available for their potential entering in the clinical setting.
Keywords: Neurodegenerative diseases, intrabody, scFv, nanotechnology, gene delivery.
Current Pharmaceutical Design
Title:Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders
Volume: 20 Issue: 38
Author(s): Alessio Cardinale, Daniela Merlo, Paolo Giunchedi and Silvia Biocca
Affiliation:
Keywords: Neurodegenerative diseases, intrabody, scFv, nanotechnology, gene delivery.
Abstract: Many neurodegenerative diseases, referred to as misfolding diseases, are characterized by the formation and accumulation of pathological extracellular and intracellular misfolded aggregates. Ageing is considered the major risk factor for neurodegenerative disorders and, due to increase of mean lifespan, the clinical relevance is growing dramatically with a urgent need to find new effective therapeutic approaches. The intracellular antibody technology is a gene-based strategy which exploits the specificity of recombinant antibodies to neutralize or modify the function of intracellular and extracellular target antigens. Intrabodies can potentially recognize all the pathological conformers of a misfolding-prone protein, and therefore they are emerging as therapeutic agents for the treatment of misfolding diseases as well as molecular tools for the understanding of their pathogenesis.
Here we focus on the application of intrabodies against two major age-related neurodegenerative disorders, Alzheimer’s disease (AD) and Parkinson’s disease (PD) and the description of in vivo gene delivery systems available for their potential entering in the clinical setting.
Export Options
About this article
Cite this article as:
Cardinale Alessio, Merlo Daniela, Giunchedi Paolo and Biocca Silvia, Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders, Current Pharmaceutical Design 2014; 20 (38) . https://dx.doi.org/10.2174/1381612820666140314121444
DOI https://dx.doi.org/10.2174/1381612820666140314121444 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Image-based Mouth Switch for People with Severe Disabilities
Recent Patents on Computer Science Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry Drug Abuse, Brain Calcification and Glutamate-Induced Neurodegeneration
Current Drug Abuse Reviews Editorial - Progress of Current Alzheimer Research
Current Alzheimer Research Protein Conformational Misfolding and Amyloid Formation: Characteristics of a New Class of Disorders that Include Alzheimers and Prion Diseases
Current Medicinal Chemistry How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches
Current Gene Therapy Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
CNS & Neurological Disorders - Drug Targets Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress
Current Neuropharmacology Inflammatory Mediators in Epilepsy
Current Pharmaceutical Design Pharmacogenetics in Psychiatry - A Useful Clinical Tool or Wishful Thinking for the Future?
Current Pharmaceutical Design G-Protein Coupled Receptors Involved in the Resolution of Inflammation: Ligands and Therapeutic Perspectives
Mini-Reviews in Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Lewy Bodies: A Spectator or Salient Killer?
CNS & Neurological Disorders - Drug Targets Mitochondria, Mitochondrial DNA and Alzheimers Disease. What Comes First?
Current Alzheimer Research New Insights into the Mechanisms of Mitochondrial Preconditioning-Triggered Neuroprotection
Current Pharmaceutical Design Editorial [Hot topic: QSAR and Complex Networks in Pharmaceutical Design, Microbiology, Parasitology, Toxicology, Cancer and Neurosciences (Executive Editor: Humberto Gonzalez-Diaz)]
Current Pharmaceutical Design The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein
Protein & Peptide Letters